Lapatinib in Combination With Radiation Diminishes Tumor Regrowth in HER2+ and Basal-Like/EGFR+ Breast Tumor Xenografts

Targeted treatment of advanced and metastatic breast cancer with lapatinib

Brendan Corkery
Norma O&amp
John Crown

September 2008

Brendan Corkery1,2, Norma O&rsquo;Donovan2, John Crown1,21St. Vincent&rsquo;s University Hos...

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial

A. Decensi
M. Puntoni
G. Pruneri
A. Guerrieri-Gonzaga
M. Lazzeroni
D. Serrano
D. Macis
H. Johansson
O. Pala
A. Luini
P. Veronesi
V. Galimberti
M.C. Dotti
G. Viale
B. Bonanni

August 2011

Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor l...

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

Diaz, R. (Ramón)
Nguewa, P.A. (Paul Alain)
Parrondo, R. (Ricardo)
Perez-Stable, C. (Carlos)
Manrique, I. (Irene)
Redrado, M. (Miriam)
Catena, R. (R.)
Collantes, M. (María)
Peñuelas-Sanchez, I. (Ivan)
Diaz-Gonzalez, J.A. (Juan Antonio)
Calvo, A. (Alfonso)

May 2010

Abstract Background: There is strong evidence demonstrating that activation of epidermal growth fac...

Lapatinib in Combination With Radiation Diminishes Tumor Regrowth in HER2+ and Basal-Like/EGFR+ Breast Tumor Xenografts

Sambade, Maria J.
Kimple, Randall J.
Camp, J. Terese
Peters, Eldon
Livasy, Chad A.
Sartor, Carolyn I.
Shields, Janiel M.

January 2010

To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor...

Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK

Sambade, Maria J.
Camp, J. Terese
Kimple, Randall J.
Sartor, Carolyn I.
Shields, Janiel M.

January 2009

We recently showed that lapatinib, an EGFR/HER2 inhibitor, radiosensitized breast cancer cells of th...

Phase I Study and Biomarker Analysis of Lapatinib and Concurrent Radiation for Locally Advanced Breast Cancer

Kimple, R. J.
Horton, J. K.
Livasy, C. A.
Shields, J. M.
Lawrence, J. A.
Chiu, W. M.
Ivanova, A.
Ollila, D. W.
Carey, L. A.
Halle, J. S.
Sartor, C. I.
Dees, E. C.

January 2012

This phase I study assessed the toxicity and safety of combining daily lapatinib with radiation ther...

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.

Leung, W-Y
Roxanis, I
Sheldon, H
Buffa, FM
Li, J-L
Harris, AL
Kong, A

March 2015

Acquired resistance to lapatinib, an inhibitor of EGFR and HER2 kinases, is common. We found that re...

Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance.

Emde, Anna
Mahlknecht, Georg
Maslak, Kerstin
Ribba, Benjamin
Sela, Michael
Possinger, Kurt
Yarden, Yosef

October 2011

International audienceThe estrogen receptor (ER) pathway and the epidermal growth factor receptor (E...

Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance

Emde, Anna
Mahlknecht, Georg
Maslak, Kerstin
Ribba, Benjamin
Sela, Michael
Possinger, Kurt
Yarden, Yosef

October 2011

AbstractThe estrogen receptor (ER) pathway and the epidermal growth factor receptor (EGFR) pathway p...

Does Lapatinib Work against HER2-negative Breast Cancers?

Ingrid A. Mayer
Carlos L. Arteaga

November 2015

Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in...

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer

Merriam PA
Sikov WM

October 2011

Priscilla Merriam, William M Sikov Department of Medicine, Division of Hematology-Oncology, Warren A...

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization [Commentary]

Gee, Julia Margaret Wendy
Nicholson, Robert Ian

January 2003

Expression of epidermal growth factor receptor (EGFR) has been associated with radioresistance in ca...

Lapatinib and 17AAG Reduce Zr-89-Trastuzumab-F(ab')(2) Uptake in SKBR3 Tumor Xenografts

Munnink, Thijs H. Oude
de Vries, Elisabeth G. E.
Vedelaar, Silke R.
Timmer-Bosscha, Hetty
Schroder, Carolina P.
Brouwers, Adrienne H.
Lub-de Hooge, Marjolijn N.

November 2012

Human epidermal growth factor receptor-2 (HER2) directed therapy potentially can be improved by insi...

Response and resistance to lapatinib in HER2-overexpressing breast cancer

Leung, W

January 2014

HER2 overexpression has been implicated in breast cancer. Lapatinib is a dual EGFR/HER2 tyrosine kin...

Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

Kimple, Randall J.
Vaseva, Angelina V.
Cox, Adrienne D.
Baerman, Kathryn M.
Calvo, Benjamin F.
Tepper, Joel E.
Shields, Janiel M.
Sartor, Carolyn I.

January 2010

Epidermal growth factor receptor family members (e.g., EGFR, HER2, HER3, and HER4) are commonly over...

Targeted treatment of advanced and metastatic breast cancer with lapatinib

Brendan Corkery
Norma O&amp
John Crown

September 2008

Brendan Corkery1,2, Norma O&rsquo;Donovan2, John Crown1,21St. Vincent&rsquo;s University Hos...

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial

A. Decensi
M. Puntoni
G. Pruneri
A. Guerrieri-Gonzaga
M. Lazzeroni
D. Serrano
D. Macis
H. Johansson
O. Pala
A. Luini
P. Veronesi
V. Galimberti
M.C. Dotti
G. Viale
B. Bonanni

August 2011

Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor l...

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

Diaz, R. (Ramón)
Nguewa, P.A. (Paul Alain)
Parrondo, R. (Ricardo)
Perez-Stable, C. (Carlos)
Manrique, I. (Irene)
Redrado, M. (Miriam)
Catena, R. (R.)
Collantes, M. (María)
Peñuelas-Sanchez, I. (Ivan)
Diaz-Gonzalez, J.A. (Juan Antonio)
Calvo, A. (Alfonso)

May 2010

Abstract Background: There is strong evidence demonstrating that activation of epidermal growth fac...

Lapatinib in Combination With Radiation Diminishes Tumor Regrowth in HER2+ and Basal-Like/EGFR+ Breast Tumor Xenografts

Sambade, Maria J.
Kimple, Randall J.
Camp, J. Terese
Peters, Eldon
Livasy, Chad A.
Sartor, Carolyn I.
Shields, Janiel M.

January 2010

To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor...

Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK

Sambade, Maria J.
Camp, J. Terese
Kimple, Randall J.
Sartor, Carolyn I.
Shields, Janiel M.

January 2009

We recently showed that lapatinib, an EGFR/HER2 inhibitor, radiosensitized breast cancer cells of th...

Phase I Study and Biomarker Analysis of Lapatinib and Concurrent Radiation for Locally Advanced Breast Cancer

Kimple, R. J.
Horton, J. K.
Livasy, C. A.
Shields, J. M.
Lawrence, J. A.
Chiu, W. M.
Ivanova, A.
Ollila, D. W.
Carey, L. A.
Halle, J. S.
Sartor, C. I.
Dees, E. C.

January 2012

This phase I study assessed the toxicity and safety of combining daily lapatinib with radiation ther...

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.

Leung, W-Y
Roxanis, I
Sheldon, H
Buffa, FM
Li, J-L
Harris, AL
Kong, A

March 2015

Acquired resistance to lapatinib, an inhibitor of EGFR and HER2 kinases, is common. We found that re...

Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance.

Emde, Anna
Mahlknecht, Georg
Maslak, Kerstin
Ribba, Benjamin
Sela, Michael
Possinger, Kurt
Yarden, Yosef

October 2011

International audienceThe estrogen receptor (ER) pathway and the epidermal growth factor receptor (E...

Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance

Emde, Anna
Mahlknecht, Georg
Maslak, Kerstin
Ribba, Benjamin
Sela, Michael
Possinger, Kurt
Yarden, Yosef

October 2011

AbstractThe estrogen receptor (ER) pathway and the epidermal growth factor receptor (EGFR) pathway p...

Does Lapatinib Work against HER2-negative Breast Cancers?

Ingrid A. Mayer
Carlos L. Arteaga

November 2015

Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in...

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer

Merriam PA
Sikov WM

October 2011

Priscilla Merriam, William M Sikov Department of Medicine, Division of Hematology-Oncology, Warren A...

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization [Commentary]

Gee, Julia Margaret Wendy
Nicholson, Robert Ian

January 2003

Expression of epidermal growth factor receptor (EGFR) has been associated with radioresistance in ca...

Lapatinib and 17AAG Reduce Zr-89-Trastuzumab-F(ab')(2) Uptake in SKBR3 Tumor Xenografts

Munnink, Thijs H. Oude
de Vries, Elisabeth G. E.
Vedelaar, Silke R.
Timmer-Bosscha, Hetty
Schroder, Carolina P.
Brouwers, Adrienne H.
Lub-de Hooge, Marjolijn N.

November 2012

Human epidermal growth factor receptor-2 (HER2) directed therapy potentially can be improved by insi...

Response and resistance to lapatinib in HER2-overexpressing breast cancer

Leung, W

January 2014

HER2 overexpression has been implicated in breast cancer. Lapatinib is a dual EGFR/HER2 tyrosine kin...

Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

Kimple, Randall J.
Vaseva, Angelina V.
Cox, Adrienne D.
Baerman, Kathryn M.
Calvo, Benjamin F.
Tepper, Joel E.
Shields, Janiel M.
Sartor, Carolyn I.

January 2010

Epidermal growth factor receptor family members (e.g., EGFR, HER2, HER3, and HER4) are commonly over...

Targeted treatment of advanced and metastatic breast cancer with lapatinib

Brendan Corkery
Norma O&amp
John Crown

September 2008

Brendan Corkery1,2, Norma O&rsquo;Donovan2, John Crown1,21St. Vincent&rsquo;s University Hos...

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial

A. Decensi
M. Puntoni
G. Pruneri
A. Guerrieri-Gonzaga
M. Lazzeroni
D. Serrano
D. Macis
H. Johansson
O. Pala
A. Luini
P. Veronesi
V. Galimberti
M.C. Dotti
G. Viale
B. Bonanni

August 2011

Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor l...

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

Diaz, R. (Ramón)
Nguewa, P.A. (Paul Alain)
Parrondo, R. (Ricardo)
Perez-Stable, C. (Carlos)
Manrique, I. (Irene)
Redrado, M. (Miriam)
Catena, R. (R.)
Collantes, M. (María)
Peñuelas-Sanchez, I. (Ivan)
Diaz-Gonzalez, J.A. (Juan Antonio)
Calvo, A. (Alfonso)

May 2010

Abstract Background: There is strong evidence demonstrating that activation of epidermal growth fac...

Lapatinib in Combination With Radiation Diminishes Tumor Regrowth in HER2+ and Basal-Like/EGFR+ Breast Tumor Xenografts

Abstract

Extracted data

Lapatinib in Combination With Radiation Diminishes Tumor Regrowth in HER2+ and Basal-Like/EGFR+ Breast Tumor Xenografts

Abstract

Extracted data

Related items

Related items